Abstract
Aim: This work was designed to explore the role of the triglyceride-glucose (TyG) index in the prediction of long-term mortality in patients with lower extremity artery disease (LEAD) undergoing endovascular revascularization. Methods: The records of 723 patients with symptomatic LEAD undergoing endovascular revascularization between January 2016 and December 2021, with long-term follow-up until December 2021, were analyzed. Results: The rate of long-term mortality was significantly higher among patients with high TyG index than patients with low TyG index. Conclusion: The TyG index is an independent predictor of long-term mortality in patients with LEAD undergoing endovascular revascularization.
Author contributions
Conception and design were carried out by O Tasbulak, M Duran, S Kahraman and M Erturk. The analysis and interpretation was done by O Tasbulak, C Can, G Demirci, AE Ulutas and AA Yalcin. Data collection was done by O Tasbulak, AY Cizgici, AK Kalkan, O Celik and AA Yalcin. The article was written by O Tasbulak and M Erturk. Critical revision of the article was done by AY Cizgici, S Kahraman and O Celik. Final approval of the article was given by O Tasbulak, G Demirci, AE Ulutas, AY Cizgici and M Erturk. Statistical analysis was done by M Duran and AA Yalcin. Overall article responsibility was given to O Tasbulak.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval from the Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital (no: 2022.05-32) and have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, informed consent has been obtained from the participants involved.